Peanut Patch Gets Fast Track
A medical skin patch to treat peanut allergies in children has received accelerated regulatory review from the U.S. Food and Drug Administration.
The Viaskin Peanut Patch, developed by the French biotechnology firm DBV Technologies, received a “breakthrough therapy” designation from the FDA, a status granted to expedite development and review of drugs or products that demonstrate significant improvement over existing therapies in treating serious or life-threatening diseases or conditions. It is the first breakthrough designation for a product designed to treat food allergies, which affect about 15 million people in the U.S.
Compiled by Katherine Kopp, a freelance writer and editor in Chapel Hill.